炎症性肠病患者结直肠异型增生的发生率与风险:全国性队列研究
基于瑞典全国队列1969–2023年54534例IBD患者,按基线异型增生分级分析未来进展为高级别异型增生或结直肠癌的风险。中位随访13.3年,无异型增生者2.3%发生未来进展,不确定型5.3%(aHR 1.85),低级别8.3%(aHR 3.51),高级别者40%发生结直肠癌(aHR 47.88)。
要点
- IBD患者基线异型增生分级越高,未来进展为高级别异型增生或结直肠癌风险越大。
- 高级别异型增生患者40%进展为结直肠癌,aHR 47.88。
- 男性、年轻发病、广泛结肠炎、原发性硬化性胆管炎和组织学炎症为风险因素。
核心结论
- IBD合并异型增生患者未来发生异型增生风险显著增加,尤其高级别异型增生患者。
- 基于风险因素的个体化监测策略对预防晚期结直肠肿瘤至关重要。
研究设计与样本
- 全国性队列研究,使用瑞典患者登记和ESPRESSO组织病理学队列,纳入1969–2023年诊断的IBD患者。
- 共54534例IBD患者,其中1320例有基线异型增生(264例不确定型、1031例低级别、25例高级别),53214例无异型增生。
- 按基线首次异型增生事件分类,主要结局为随访期间未来晚期结直肠肿瘤(高级别异型增生或结直肠癌),采用Cox回归估计调整风险比(aHR)和95%置信区间(CI)。
主要发现
- 中位随访13.3年,无异型增生患者2.3%发生未来晚期结直肠肿瘤。
- 不确定型异型增生患者5.3%发生未来晚期结直肠肿瘤(aHR 1.85;95% CI 1.09-3.15)。
- 低级别异型增生患者8.3%发生未来晚期结直肠肿瘤(aHR 3.51;95% CI 2.77-4.45)。
- 高级别异型增生患者40%发生结直肠癌(aHR 47.88;95% CI 25.53-89.80)。
- 未来异型增生风险因素包括男性、诊断时较年轻、广泛结肠炎、原发性硬化性胆管炎和组织学炎症。
临床怎么用
- 对IBD患者应依据基线异型增生分级进行风险分层监测。
- 高级别异型增生患者进展为结直肠癌风险极高,需加强监测或干预。
- 具备男性、年轻发病、广泛结肠炎、原发性硬化性胆管炎或组织学炎症等风险因素者应个体化监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Individuals with inflammatory bowel disease (IBD) have an elevated risk of colorectal neoplasia (CRN), including colorectal dysplasia and cancer (CRC). Despite surveillance strategies to prevent CRC, the clinical course of dysplasia types remains poorly understood. METHODS: We conducted a nationwide cohort study using the Swedish Patient Register and the ESPRESSO histopathology cohort to identify patients diagnosed with IBD between 1969 and 2023. Patients were classified according to their first (baseline) incident episode of dysplasia (no dysplasia [ND]; indefinite [IND]; low-grade [LGD]; high-grade [HGD]). Our primary outcome was future advanced CRN (HGD or CRC) during follow-up. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) were estimated using Cox regression. RESULTS: We identified 54,534 patients with IBD, including 1320 with a first (baseline) episode of dysplasia (264 IND, 1031 LGD, 25 HGD), and 53,214 with ND. Over a median follow-up of 13.3 years, 2.3% of patients with ND had future advanced CRN compared with 5.3% of patients with IND (aHR, 1.85; 95% CI, 1.09-3.15) and 8.3% of patients with LGD (aHR, 3.51; 95% CI, 2.77-4.45). Of those with HGD, 40% developed CRC (aHR, 47.88; 95% CI, 25.53-89.80). Risk factors for future dysplasia included male sex, younger age at diagnosis, extensive colitis, primary sclerosing cholangitis, and histologic inflammation. CONCLUSIONS: Patients with IBD and dysplasia have a significantly increased risk of future dysplasia, particularly among patients with HGD. Personalized surveillance strategies based on risk factors are critical for preventing advanced CRN.
引用
- Axelrad JE, Faye AS, Söderling J, et al. Incidence and Risk of Colorectal Dysplasia in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2026. PMID: 41708041. doi:10.1016/j.cgh.2026.01.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。